Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer

C. H. Yang, C. M. Tsai, L. S. Wang, Y. C. Lee, C. J. Chang, L. T. Lui, S. H. Yen, C. Hsu, A. L. Cheng, M. Y. Liu, S. C. Chiang, Y. M. Chen, K. T. Luh, M. H. Huang, P. C. Yang, R. P. Perng

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The role of new cytotoxic agents like gemcitabine has not yet been proven in the neoadjuvant settings. We designed a phase II study to test the feasibility of using gemcitabine and cisplatin before local treatment for stage III non-small cell lung cancer patients. Patients received three cycles of induction chemotherapy of gemcitabine (1000 mg m-2, days 1, 8, 15) and cisplatin (90 mg m-2, day 15) every 4 weeks before evaluation for operability. Operable patients underwent radical resection. Inoperable patients and patients who had incomplete resection received concurrent chemoradiotherapy with daily low dose cisplatin. All patients who did not progress after local treatment received three more cycles of adjuvant chemotherapy of gemcitabine and cisplatin. Fifty-two patients received induction treatment. Two patients had complete response and 31 patients had partial response (response rate 63.5%) after induction chemotherapy. Thirty-six patients (69%) were operable. Eighteen patients (35%) had their tumours completely resected. Two patients had pathological complete response. Median overall survival was 19.1 months, projected 1-year survival was 66% and 2-year survival was 34%. Three cycles of gemcitabine and cisplatin is effective and can be used as induction treatment before surgery for locally advanced non-small cell lung cancer patients.

Original languageEnglish
Pages (from-to)190-195
Number of pages6
JournalBritish Journal of Cancer
Volume86
Issue number2
DOIs
Publication statusPublished - Jan 21 2002
Externally publishedYes

Fingerprint

gemcitabine
Non-Small Cell Lung Carcinoma
Cisplatin
Therapeutics
Induction Chemotherapy
Survival

Keywords

  • Gemcitabine
  • Locally advanced NSCLC
  • Neoadjuvant chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Yang, C. H., Tsai, C. M., Wang, L. S., Lee, Y. C., Chang, C. J., Lui, L. T., ... Perng, R. P. (2002). Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer. British Journal of Cancer, 86(2), 190-195. https://doi.org/10.1038/sj.bjc.6600044

Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer. / Yang, C. H.; Tsai, C. M.; Wang, L. S.; Lee, Y. C.; Chang, C. J.; Lui, L. T.; Yen, S. H.; Hsu, C.; Cheng, A. L.; Liu, M. Y.; Chiang, S. C.; Chen, Y. M.; Luh, K. T.; Huang, M. H.; Yang, P. C.; Perng, R. P.

In: British Journal of Cancer, Vol. 86, No. 2, 21.01.2002, p. 190-195.

Research output: Contribution to journalArticle

Yang, CH, Tsai, CM, Wang, LS, Lee, YC, Chang, CJ, Lui, LT, Yen, SH, Hsu, C, Cheng, AL, Liu, MY, Chiang, SC, Chen, YM, Luh, KT, Huang, MH, Yang, PC & Perng, RP 2002, 'Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer', British Journal of Cancer, vol. 86, no. 2, pp. 190-195. https://doi.org/10.1038/sj.bjc.6600044
Yang, C. H. ; Tsai, C. M. ; Wang, L. S. ; Lee, Y. C. ; Chang, C. J. ; Lui, L. T. ; Yen, S. H. ; Hsu, C. ; Cheng, A. L. ; Liu, M. Y. ; Chiang, S. C. ; Chen, Y. M. ; Luh, K. T. ; Huang, M. H. ; Yang, P. C. ; Perng, R. P. / Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer. In: British Journal of Cancer. 2002 ; Vol. 86, No. 2. pp. 190-195.
@article{c226810f5d914941a55c7feb1b6b73e3,
title = "Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer",
abstract = "The role of new cytotoxic agents like gemcitabine has not yet been proven in the neoadjuvant settings. We designed a phase II study to test the feasibility of using gemcitabine and cisplatin before local treatment for stage III non-small cell lung cancer patients. Patients received three cycles of induction chemotherapy of gemcitabine (1000 mg m-2, days 1, 8, 15) and cisplatin (90 mg m-2, day 15) every 4 weeks before evaluation for operability. Operable patients underwent radical resection. Inoperable patients and patients who had incomplete resection received concurrent chemoradiotherapy with daily low dose cisplatin. All patients who did not progress after local treatment received three more cycles of adjuvant chemotherapy of gemcitabine and cisplatin. Fifty-two patients received induction treatment. Two patients had complete response and 31 patients had partial response (response rate 63.5{\%}) after induction chemotherapy. Thirty-six patients (69{\%}) were operable. Eighteen patients (35{\%}) had their tumours completely resected. Two patients had pathological complete response. Median overall survival was 19.1 months, projected 1-year survival was 66{\%} and 2-year survival was 34{\%}. Three cycles of gemcitabine and cisplatin is effective and can be used as induction treatment before surgery for locally advanced non-small cell lung cancer patients.",
keywords = "Gemcitabine, Locally advanced NSCLC, Neoadjuvant chemotherapy",
author = "Yang, {C. H.} and Tsai, {C. M.} and Wang, {L. S.} and Lee, {Y. C.} and Chang, {C. J.} and Lui, {L. T.} and Yen, {S. H.} and C. Hsu and Cheng, {A. L.} and Liu, {M. Y.} and Chiang, {S. C.} and Chen, {Y. M.} and Luh, {K. T.} and Huang, {M. H.} and Yang, {P. C.} and Perng, {R. P.}",
year = "2002",
month = "1",
day = "21",
doi = "10.1038/sj.bjc.6600044",
language = "English",
volume = "86",
pages = "190--195",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer

AU - Yang, C. H.

AU - Tsai, C. M.

AU - Wang, L. S.

AU - Lee, Y. C.

AU - Chang, C. J.

AU - Lui, L. T.

AU - Yen, S. H.

AU - Hsu, C.

AU - Cheng, A. L.

AU - Liu, M. Y.

AU - Chiang, S. C.

AU - Chen, Y. M.

AU - Luh, K. T.

AU - Huang, M. H.

AU - Yang, P. C.

AU - Perng, R. P.

PY - 2002/1/21

Y1 - 2002/1/21

N2 - The role of new cytotoxic agents like gemcitabine has not yet been proven in the neoadjuvant settings. We designed a phase II study to test the feasibility of using gemcitabine and cisplatin before local treatment for stage III non-small cell lung cancer patients. Patients received three cycles of induction chemotherapy of gemcitabine (1000 mg m-2, days 1, 8, 15) and cisplatin (90 mg m-2, day 15) every 4 weeks before evaluation for operability. Operable patients underwent radical resection. Inoperable patients and patients who had incomplete resection received concurrent chemoradiotherapy with daily low dose cisplatin. All patients who did not progress after local treatment received three more cycles of adjuvant chemotherapy of gemcitabine and cisplatin. Fifty-two patients received induction treatment. Two patients had complete response and 31 patients had partial response (response rate 63.5%) after induction chemotherapy. Thirty-six patients (69%) were operable. Eighteen patients (35%) had their tumours completely resected. Two patients had pathological complete response. Median overall survival was 19.1 months, projected 1-year survival was 66% and 2-year survival was 34%. Three cycles of gemcitabine and cisplatin is effective and can be used as induction treatment before surgery for locally advanced non-small cell lung cancer patients.

AB - The role of new cytotoxic agents like gemcitabine has not yet been proven in the neoadjuvant settings. We designed a phase II study to test the feasibility of using gemcitabine and cisplatin before local treatment for stage III non-small cell lung cancer patients. Patients received three cycles of induction chemotherapy of gemcitabine (1000 mg m-2, days 1, 8, 15) and cisplatin (90 mg m-2, day 15) every 4 weeks before evaluation for operability. Operable patients underwent radical resection. Inoperable patients and patients who had incomplete resection received concurrent chemoradiotherapy with daily low dose cisplatin. All patients who did not progress after local treatment received three more cycles of adjuvant chemotherapy of gemcitabine and cisplatin. Fifty-two patients received induction treatment. Two patients had complete response and 31 patients had partial response (response rate 63.5%) after induction chemotherapy. Thirty-six patients (69%) were operable. Eighteen patients (35%) had their tumours completely resected. Two patients had pathological complete response. Median overall survival was 19.1 months, projected 1-year survival was 66% and 2-year survival was 34%. Three cycles of gemcitabine and cisplatin is effective and can be used as induction treatment before surgery for locally advanced non-small cell lung cancer patients.

KW - Gemcitabine

KW - Locally advanced NSCLC

KW - Neoadjuvant chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=18244403565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18244403565&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6600044

DO - 10.1038/sj.bjc.6600044

M3 - Article

C2 - 11870504

AN - SCOPUS:18244403565

VL - 86

SP - 190

EP - 195

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -